GlassScriptPhysician profile
Laura Ashley Short
NPI 1013553627
$1,991.14
in general payments reported to CMS, 2019-2025
24 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $496 · 2022: $500 · 2023: $441 · 2024: $326 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $476.53 | 2021-2025 | |
| Glaxosmithkline, LLC. | $223.84 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $179.21 | 2021-2023 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $166.98 | 2022-2024 | Rexulti |
| Gilead Sciences, INC. | $146.36 | 2024 | Epclusa |
| Vanda Pharmaceuticals INC. | $100.85 | 2021-2025 | Fanapt |
| Lilly USA, LLC | $90.80 | 2022-2025 | Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.14 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $77.64 | 2022-2023 | Trintellix |
| Axsome Therapeutics, INC. | $70.34 | 2023 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $41.35 | 2022-2023 | Breztri |
| Amgen INC. | $39.73 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $39.36 | 2021-2022 | |
| Astellas Pharma US INC | $35.65 | 2022-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.73 | 2021-2023 | Stiolto Respimat |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.04 | 2021-2022 | |
| Exact Sciences Corporation | $31.96 | 2024-2025 | Cologuard Collection Kit |
| Csl Behring | $30.95 | 2022-2023 | Kcentra |
| Corcept Therapeutics | $24.01 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $16.73 | 2023 | |
| Idorsia Pharmaceuticals US INC | $16.05 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $13.59 | 2021 | |
| Pfizer INC. | $13.57 | 2023 | |
| Dexcom, INC. | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Short listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.